PierianDx Clinical Genomicist Workspace
PierianDx said that its Clinical Genomicist Workspace genomics workflow and analysis software now supports clinical microarray technology (CMA). CMA enhancements within CGW include workflow integration to submit processed microarray results from a batch of samples to generation of a templated report without user intervention; the ability to review, sort, and filter copy number variants (CNV) as well as loss of heterozygosity (LOH) segments and associated quality information; the ability to set laboratory-specific validation filters for CNV and LOH segments as well as specific panel- and case-specific filters; clinical interpretations that are automatically inferred in patient cases for review and editing; and an updated knowledgebase that includes published literature for articles that mention cytogenetic positions, genes, and phenotypes associated with a patient case.
ARUP Laboratories/IDbyDNA Explify Respiratory
ARUP Laboratories and IDbyDNA have launched Explify Respiratory, a next-generation sequencing-based test for respiratory infections. Explify Respiratory detects more than 200 common and rare bacterial, fungal, and viral respiratory pathogens with a single test. It is powered by IDbyDNA's Taxonomer software, a DNA search engine that can rapidly identify any organism by its genetic material. The test is the first in a line of tests that ARUP Labs and IDbyDNA plan to launch as part of a previously announced strategic partnership to develop and commercialize infectious disease testing using metagenomics.
Horizon Discovery CRISPRi and CRISPRa Screening Services
Horizon Discovery announced that it has expanded its functional genomic screening portfolio to include CRISPRi (interference) and CRISPRa (activation) screening services. Horizon's CRISPRi/CRISPRa screening platform substantially broadens the range of possible studies through the capacity to reduce or increase, rather than completely eliminating gene expression, the company said. This enables customers to address critical gaps in target ID and validation as they work to develop novel and more effective drug therapies. The screening capabilities are based on the company's highly optimised CRISPR knockout screening platform. Horizon has also developed an enhanced solution that combines both CRISPRi and CRISPRa screening. This combined solution can reveal 'switch'-like genes that display opposing effects when activated or inhibited in the presence of the drug of interest.
For more new products and services, please visit the New Products page on our website.